SpringWorks Therapeutics, Inc.(SWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

SWTX SpringWorks Therapeutics, Inc.

停牌 07-10 08:36:05 EDT

46.99

+0.00

0.00%

最高46.99	最低46.99	成交量0.00
今开46.99	昨收46.99	日振幅0.00%
总市值35.41亿	流通市值34.86亿	总股本7,535万
成交额2.35亿	换手率0.00%	流通股本7,419万
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"SWTX","market":"US","secType":"STK","nameCN":"SpringWorks Therapeutics, Inc.","latestPrice":46.99,"timestamp":1751313600000,"preClose":46.99,"halted":3,"volume":0,"delay":0,"floatShares":74190413,"shares":75348995,"eps":-3.412527,"marketStatus":"停牌","change":0,"latestTime":"07-10 08:36:05 EDT","open":46.99,"high":46.99,"low":46.99,"amount":235410028.645952,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.412527,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1752154200000},"marketStatusCode":1,"adr":0,"listingDate":1568347200000,"exchange":"NASDAQ","adjPreClose":46.99,"volumeRatio":0},"requestUrl":"/m/hq/s/SWTX","defaultTab":"news","newsList":[{"id":"2531321710","title":"HC Wainwright & Co.：下调SpringWorks Therapeutics评级，由买入调整至中性评级, 目标价由74.00美元调整至47.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531321710","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531321710?lang=zh_cn&edition=full","pubTime":"2025-04-30 20:41","pubTimestamp":1746016891,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：下调SpringWorks Therapeutics(SWTX.US)评级，由买入调整至中性评级, 目标价由74.00美元调整至47.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430204503974b9496&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250430204503974b9496&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SWTX","LENZ"],"gpt_icon":0},{"id":"2531925567","title":"巴克莱：下调SpringWorks Therapeutics评级，由增持调整至持股观望评级, 目标价由63.00美元调整至47.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2531925567","media":"金融界","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2531925567?lang=zh_cn&edition=full","pubTime":"2025-04-29 01:33","pubTimestamp":1745861612,"startTime":"0","endTime":"0","summary":"巴克莱：下调SpringWorks Therapeutics(SWTX.US)评级，由增持调整至持股观望评级, 目标价由63.00美元调整至47.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042901352394e62f9b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042901352394e62f9b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","SWTX"],"gpt_icon":0},{"id":"2530449137","title":"达成协议！默克39亿美元收购SpringWorks","url":"https://stock-news.laohu8.com/highlight/detail?id=2530449137","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530449137?lang=zh_cn&edition=full","pubTime":"2025-04-28 15:42","pubTimestamp":1745826173,"startTime":"0","endTime":"0","summary":"德国医疗保健和材料集团默克周一表示，该公司已达成协议，将以39亿美元的股权价值收购美国生物技术公司SpringWorks $Therapeutics$ $$，以提振其抗癌药物业务。默克表示，扣除SpringWorks持有的现金，每股47美元的现金收购价格相当于约39亿美元的股权价值，相当于34亿美元的企业价值。收购SpringWorks将成为这家德国医疗保健和科技集团近年来最大的制药交易之一，推动其正在进行的建立癌症治疗业务的努力。2015年，默克同意以170亿美元收购美国实验室设备供应商Sigma-Aldrich。","market":"hk","thumbnail":"https://static.tigerbbs.com/93c3dba7c4b0e443e40fe6df5639434d","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/93c3dba7c4b0e443e40fe6df5639434d"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1286227.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"达成协议！默克39亿美元收购SpringWorks","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SWTX"],"gpt_icon":1},{"id":"2530182446","title":"德国默克即将达成35亿美元收购交易 欲将SpringWorks(SWTX.US)纳入麾下","url":"https://stock-news.laohu8.com/highlight/detail?id=2530182446","media":"智通财经网","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530182446?lang=zh_cn&edition=full","pubTime":"2025-04-25 20:07","pubTimestamp":1745582866,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据《华尔街日报》最新报道，德国默克集团 当前非常接近达成一项大约35亿美元的协议，收购癌症以及罕见病药物知名开发商 SpringWorks Therapeutics，消息传出后 SpringWorks 股价盘中触及当日最高点，截至周四收盘SpringWorks股价涨幅高达9%。作为对比，SpringWorks股价当前徘徊于44.93美元。总部位于德国达姆施塔特的默克随后证实，正在与SpringWorks 洽谈收购事宜。今年2月，美国卫生监管机构批准了SpringWorks的基因疾病药物gomez kli。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1285322.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK4139","SWTX"],"gpt_icon":0},{"id":"2530942696","title":"德国默克拟以35亿美元收购SpringWorks(SWTX.US)的谈判进入后期阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2530942696","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2530942696?lang=zh_cn&edition=full","pubTime":"2025-04-25 11:37","pubTimestamp":1745552260,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，德国默克公司周四表示，以约35亿美元收购美国SpringWorks Therapeutics的谈判已进入后期阶段，该交易可能使默克获得最近批准的一种罕见疾病药物，并扩大其实验性癌症治疗产品组合。2015年，默克同意以170亿美元收购美国实验室设备供应商Sigma-Aldrich。自那以来，SpringWorks的股价已经下跌了17%。媒体报道默克接近达成交易的消息后，SpringWorks股价收盘上涨9%，交易最早可能于下周一完成。今年2月，美国卫生监管机构批准了SpringWorks的基因疾病药物gomez kli。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1284697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"德国默克拟以35亿美元收购SpringWorks(SWTX.US)的谈判进入后期阶段","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["SWTX","BK4139"],"gpt_icon":0},{"id":"2529586015","title":"Springworks Therapeutics, Inc.盘中异动 大幅拉升5.50%报39.10美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2529586015","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2529586015?lang=zh_cn&edition=full","pubTime":"2025-04-22 21:30","pubTimestamp":1745328650,"startTime":"0","endTime":"0","summary":"北京时间2025年04月22日21时30分，Springworks Therapeutics, Inc.股票出现异动，股价大幅上涨5.50%。Springworks Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.00%。Springworks Therapeutics, Inc.公司简介：SpringWorks Therapeutics Inc 是一家临床阶段的生物制药公司，采用精准医疗方法收购、开发和商业化改变生命的药物，为遭受毁灭性罕见疾病和癌症困扰的得不到充分服务的患者群体提供服务。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042221305194de31c6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025042221305194de31c6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK4139","BK4007","SWTX","LENZ"],"gpt_icon":0},{"id":"2518784162","title":"Springworks Therapeutics, Inc.盘中异动 早盘股价大跌5.28%报46.94美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518784162","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2518784162?lang=zh_cn&edition=full","pubTime":"2025-03-10 21:49","pubTimestamp":1741614547,"startTime":"0","endTime":"0","summary":"北京时间2025年03月10日21时49分，Springworks Therapeutics, Inc.股票出现异动，股价大幅跳水5.28%。Springworks Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.24%。Springworks Therapeutics, Inc.公司简介：SpringWorks Therapeutics Inc 是一家处于临床阶段的生物制药公司，该公司采用精准医疗的方法，获取、开发和商业化改变生命的药物，用于治疗服务不足的罕见病和癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214907abf302ff&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310214907abf302ff&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LENZ","BK4139","SWTX"],"gpt_icon":0},{"id":"2513756416","title":"Springworks Therapeutics, Inc.2024财年实现净利润-2.58亿美元，同比增加20.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2513756416","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513756416?lang=zh_cn&edition=full","pubTime":"2025-02-24 00:00","pubTimestamp":1740326437,"startTime":"0","endTime":"0","summary":"2月24日，Springworks Therapeutics, Inc.公布财报，公告显示公司2024财年净利润为-2.58亿美元，同比增加20.62%；其中营业收入为1.92亿美元，同比增加3422.94%，每股基本收益为-3.48美元。从资产负债表来看，Springworks Therapeutics, Inc.总负债1.06亿美元，其中短期债务1.73百万美元，资产负债比为5.54，流动比率为0.04。机构评级：截至2025年2月24日，当前有8家机构对Springworks Therapeutics, Inc.目标价做出预测，其中目标均价为72.88美元，其中最低目标价为63.00美元，最高目标价为87.00美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000057a250cde9&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250224000057a250cde9&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SWTX","LENZ"],"gpt_icon":0},{"id":"2513216265","title":"HC Wainwright & Co.：重申SpringWorks Therapeutics(SWTX.US)评级，由买入调整至买入评级, 目标价由74.00美元调整至74.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2513216265","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2513216265?lang=zh_cn&edition=full","pubTime":"2025-02-22 02:34","pubTimestamp":1740162872,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申SpringWorks Therapeutics(SWTX.US)评级，由买入调整至买入评级, 目标价由74.00美元调整至74.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/22023448321212.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["LENZ","SWTX"],"gpt_icon":0},{"id":"1130788003","title":"异动解读 | 因取消财报会议引发被收购预期,SpringWorks Therapeutics盘前大涨16.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=1130788003","media":"异动解读","labels":["merge","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130788003?lang=zh_cn&edition=full","pubTime":"2025-02-20 20:38","pubTimestamp":1740055102,"startTime":"0","endTime":"0","summary":"SpringWorks Therapeutics公司(SWTX)今日在盘前交易中大涨16.35%,引起了市场热烈讨论。\n\n导致该公司股价大涨的原因主要是其取消了季度财报电话会议,这引发了该公司与德国默克公司潜在收购谈判仍在继续的预期。据悉,路透社此前曾报道过默克公司正在就收购SpringWorks进行谈判。\n\n除了收购预期之外,SpringWorks第四季度营收6150万美元也超出分析师预期,这进一步助长了该公司被收购的猜测。市场显然对此作出积极反应。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"异动解读 | 因取消财报会议引发被收购预期,SpringWorks Therapeutics盘前大涨16.35%","news_tag":"merge,movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SWTX"],"gpt_icon":0},{"id":"1130961294","title":"SpringWorks Therapeutics 2024财年GAAP每股收益$(3.48)低于$(3.06)预期，销售额$1.9159亿高于$1.9092亿预估","url":"https://stock-news.laohu8.com/highlight/detail?id=1130961294","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1130961294?lang=zh_cn&edition=full","pubTime":"2025-02-20 19:52","pubTimestamp":1740052348,"startTime":"0","endTime":"0","summary":"SpringWorks Therapeutics  报告2024财年每股亏损$，低于分析师普遍预计的$，差异为13.73%。公司报告季度销售额为1.9159亿美元，高于分析师普遍预计的1.9092亿美元，差异为0.35%。以上内容来自Benzinga Earnings专栏，原文如下：SpringWorks $Therapeutics$  reported quarterly losses of $ per share which missed the analyst consensus estimate of $ by 13.73 percent.  The company reported quarterly sales of $191.59 million which beat the analyst consensus estimate of $190.92 million by 0.35 percent.","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SWTX","LENZ"],"gpt_icon":0},{"id":"2510049376","title":"HC Wainwright & Co.：重申SpringWorks Therapeutics(SWTX.US)评级，由买入调整至买入评级, 目标价由74.00美元调整至74.00美元。","url":"https://stock-news.laohu8.com/highlight/detail?id=2510049376","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510049376?lang=zh_cn&edition=full","pubTime":"2025-02-12 20:55","pubTimestamp":1739364948,"startTime":"0","endTime":"0","summary":"HC Wainwright & Co.：重申SpringWorks Therapeutics(SWTX.US)评级，由买入调整至买入评级, 目标价由74.00美元调整至74.00美元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/02/12205548120951.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SWTX","LENZ"],"gpt_icon":0},{"id":"1124949677","title":"异动解读 | FDA批准SpringWorks遗传疾病新药,公司盘后大涨7.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124949677","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124949677?lang=zh_cn&edition=full","pubTime":"2025-02-12 06:58","pubTimestamp":1739314708,"startTime":"0","endTime":"0","summary":"SpringWorks Therapeutics公司在盘后交易中股价大涨7.02%,引起了市场广泛关注。根据新闻报道,导致该公司股价大涨的主要原因是:美国食品药品监督管理局 批准了SpringWorks的新药Gomekli用于治疗一种罕见的遗传性疾病。之前只有阿斯利康公司的Koselugo获批用于治疗NF1儿童患者,而SpringWorks的Gomekli则是首个获批可用于成人和2岁及以上儿童患者的NF1口服药物。此外,据报道默克公司正在就收购SpringWorks进行深入谈判。如果收购成功,将进一步帮助这家生物科技公司推广新获批药物并拓展产品线。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SWTX"],"gpt_icon":0},{"id":"1148552946","title":"异动解读 | 默克有意收购引发SpringWorks股价盘后大跌近6%","url":"https://stock-news.laohu8.com/highlight/detail?id=1148552946","media":"异动解读","labels":["merge","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1148552946?lang=zh_cn&edition=full","pubTime":"2025-02-12 05:54","pubTimestamp":1739310872,"startTime":"0","endTime":"0","summary":"SpringWorks Therapeutics公司今日盘后股价大跌近6%,引发市场关注。\n\n根据相关报道,德国医药巨头默克公司正在就收购SpringWorks进行深入谈判,这是导致该股价暴跌的主要原因。\n\n作为一家专注罕见病和肿瘤药物研发的生物制药公司,SpringWorks去年底刚推出治疗罕见肿瘤的药品Ogsiveo,还有望获批另一潜在重磅新药。这或许吸引了默克公司的兴趣,进而与SpringWorks进行谈判。分析称,若收购成功,将有利于默克加强在生物制药和罕见病领域的布局。\n","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"merge,movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SWTX"],"gpt_icon":0},{"id":"1164462951","title":"异动解读 | 因医药巨头默克洽购传闻 SpringWorks Therapeutics盘中大跌5%","url":"https://stock-news.laohu8.com/highlight/detail?id=1164462951","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1164462951?lang=zh_cn&edition=full","pubTime":"2025-02-11 23:44","pubTimestamp":1739288665,"startTime":"0","endTime":"0","summary":"SpringWorks Therapeutics公司今日盘中大幅下跌5%,引发了市场的广泛关注。据相关报道,导致该股暴跌的主要原因是德国医药公司默克正在就收购该公司进行深入谈判。而SpringWorks是一家专注于开发科创药物的生物制药公司,主要研究内容针对多种罕见疾病和癌症。伴随SpringWorks产品线的不断壮大,或许吸引了以默克为首的业内巨头。因此,市场分析认为,默克此次收购SpringWorks,有望为其未来发展注入新的动力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["SWTX"],"gpt_icon":0},{"id":"2510487281","title":"默沙东(MRK)正就收购美国制药商SpringWorks(SWTX)进行深入谈判","url":"https://stock-news.laohu8.com/highlight/detail?id=2510487281","media":"金吾财讯","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510487281?lang=zh_cn&edition=full","pubTime":"2025-02-11 16:28","pubTimestamp":1739262495,"startTime":"0","endTime":"0","summary":"金吾财讯 | 默沙东(MRK)周一表示，正就收购美国癌症和罕见疾病制药商SpringWorks Therapeutics(SWTX)进行深入谈判。据媒体当天早些时候援引三位消息人士称，如果谈判成功，可能会在未来几周签署协议。他们没有透露正在讨论的具体条款。总部位于康涅狄格州斯坦福的SpringWorks于2019年在纽约上市，是一家商业阶段的生物技术公司，开发用于治疗各种癌症的药物，包括罕见肿瘤和子宫癌。美国医疗保健行业的交易活动在2024年有所放缓后，目前正显示出回暖的迹象。强生公司上个月同意以约146亿美元收购Intra-Cellular Therapeutics。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"285295","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1023059063.AUD","BK4585","LU1066051498.USD","LU0289739699.SGD","BK4534","LU1093756325.SGD","LU0211331839.USD","LU0070302665.USD","IE00BLSP4452.SGD","LU0106261372.USD","LU0265550946.USD","LU2361044949.HKD","SG9999013999.USD","LU0203347892.USD","LU0985320562.USD","LU0122379950.USD","LU1983299246.USD","IE00B2B36J28.USD","LU2324357040.USD","SG9999014575.USD","LU0203345920.USD","LU1162221912.USD","IE00BBT3K403.USD","BK4559","BK1191","LU1037948541.HKD","SG9999002232.USD","IE000M9KFDE8.USD","LU2089984988.USD","LU1571399168.USD","LU0320765489.SGD","LU1291159041.SGD","LU0965509010.AUD","LU1699723380.USD","LU0965508806.USD","LU1974910355.USD","LU1116320737.USD","BK4533","IE0002141913.USD","LU0861579265.USD","SWTX","LU1917777945.USD","LU1057294990.SGD","SG9999014567.USD","SG9999001176.SGD","LU1066053197.SGD","01477","MRK","LU0058720904.USD","IE00BN8TJ469.HKD"],"gpt_icon":0},{"id":"1144010287","title":"默克洽购美国生物制药公司SpringWorks","url":"https://stock-news.laohu8.com/highlight/detail?id=1144010287","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1144010287?lang=zh_cn&edition=full","pubTime":"2025-02-11 15:59","pubTimestamp":1739260784,"startTime":"0","endTime":"0","summary":"关键条件尚未满足。","market":"us","thumbnail":"https://static.tigerbbs.com/b4dc3092ae6ffcac01edfc3590364a28","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/b4dc3092ae6ffcac01edfc3590364a28"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2025-02-11/doc-inekawwf6692871.shtml","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":"默克洽购美国生物制药公司SpringWorks","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"XLCJ","symbols":["SWTX"],"gpt_icon":0},{"id":"2510810268","title":"美股异动 | SpringWorks Therapeutics(SWTX.US)大涨34% 与默克洽谈收购事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2510810268","media":"智通财经","labels":["corporation","merge","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2510810268?lang=zh_cn&edition=full","pubTime":"2025-02-11 08:21","pubTimestamp":1739233299,"startTime":"0","endTime":"0","summary":"智通财经获悉，默克公司表示，收购美国癌症和罕见疾病制药公司SpringWorks Therapeutics的谈判正在进行中，这使得这家美国癌症和罕见疾病制药公司的股价周一飙升34%，市值超过40亿美元。总部位于德国的默克公司证实了这一报道。SpringWorks的一种药物Ogsiveo在美国被批准用于治疗成人结缔组织肿瘤。彭博分析师Michael Shah在一份报告中表示，收购SpringWorks将补充默克的肿瘤业务，到2030年，每年的销售额可能会增加15亿欧元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1248104.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation,merge,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BSNM7G36.USD","LU1037948541.HKD","LU1699723380.USD","IE00BN8TJ469.HKD","LU2023250504.SGD","LU2106854487.HKD","LU1066051498.USD","LENZ","LU1917777945.USD","MRK","BK4585","LU1057294990.SGD","IE00B1BXHZ80.USD","LU1061106388.HKD","LU1116320901.HKD","IE00BJJMRZ35.SGD","LU0265550359.USD","LU0203345920.USD","LU0208291251.USD","LU0106261372.USD","LU2324357040.USD","IE00BLSP4239.USD","LU1585245621.USD","LU0965509101.SGD","LU1037948897.HKD","LU1989772840.SGD","SG9999001176.USD","LU0861579265.USD","SG9999014575.USD","IE00BBT3K403.USD","LU1093756168.USD","SWTX","LU1934455194.USD","LU1974910355.USD","LU2361044865.SGD","LU1291159041.SGD","LU0320765646.SGD","LU2361044949.HKD","LU2461242641.AUD","SG9999013999.USD","SG9999002232.USD","LU1066053197.SGD","LU1066051811.HKD","LU1116320737.USD","BK4588","IE000M9KFDE8.USD","LU0965508806.USD","LU1162221912.USD","IE00BLSP4452.SGD","LU0289739699.SGD"],"gpt_icon":1},{"id":"2508216457","title":"Springworks Therapeutics, Inc.盘中异动 早盘股价大涨5.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508216457","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2508216457?lang=zh_cn&edition=full","pubTime":"2025-02-04 22:38","pubTimestamp":1738679901,"startTime":"0","endTime":"0","summary":"北京时间2025年02月04日22时38分，Springworks Therapeutics, Inc.股票出现波动，股价快速拉升5.14%。Springworks Therapeutics, Inc.股票所在的生物技术行业中，整体涨幅为0.10%。Springworks Therapeutics, Inc.公司简介：SpringWorks Therapeutics Inc 是一家处于临床阶段的生物制药公司，该公司采用精准医疗的方法，获取、开发和商业化改变生命的药物，用于治疗服务不足的罕见病和癌症患者。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223821987a4b7c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250204223821987a4b7c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["SWTX","LENZ","BK4139"],"gpt_icon":0},{"id":"2505001388","title":"【券商聚焦】摩根大通：2025年1月美国分析师关注名单出炉","url":"https://stock-news.laohu8.com/highlight/detail?id=2505001388","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2505001388?lang=zh_cn&edition=full","pubTime":"2025-01-24 12:13","pubTimestamp":1737692030,"startTime":"0","endTime":"0","summary":"金吾财讯 | 摩根大通发布2025年1月美国分析师关注名单，多家公司被圈定为“买入”评级。消费板块里，成长型公司Abercrome & Fitch 目标价204美元；通用汽车则被看作价值股，目标价64美元。医疗保健行业中，众多成长型股票备受关注。如Eli Lily & Company目标价1100美元；Vertex Pharmaceuticals目标价280美元。在科技领域，微软作为成长股，目标价465美元；Broadcom目标价250美元。此外，名单还包含了近期四周的新增和移除股票信息。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/OTE1MjMxNjI4NTkwNjg5MDI0.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/OTE1MjMxNjI4NTkwNjg5MDI0.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"284688","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0912757837.SGD","LU0211327993.USD","BK4533","AGCO","BK4581","LU1093756325.SGD","LU0310799852.SGD","LU1032466523.USD","IE00BBT3K403.USD","BK4574","SWTX","JPM","LU1153585028.USD","IE00B19Z3B42.SGD","LU0211328371.USD","BK4152","LU2430703095.HKD","IE00BYXW3230.USD","AVGO","CHRW","LU2108987350.USD","LU2602419157.SGD","LU0070302665.USD","LU1162221912.USD","LU1934455194.USD","LU0198837287.USD","SG9999001440.SGD","LU0942090050.USD","LU0256863902.USD","BK4515","GM","LU2360106780.USD","LU2505996681.GBP","IE00BK4W5M84.HKD","VRTX","IE00BJLML261.HKD","LU0553294199.USD","IE00BKDWB100.SGD","LU0348723411.USD","IE00BVYPNV92.GBP","LU2324357040.USD","LU1093756168.USD","LU1670711040.USD","IE00B775SV38.USD","LU0433182093.SGD","LU2237443895.HKD","LU2347655156.SGD","LU0096362180.USD","LU0211326839.USD","LU1815333072.USD"],"gpt_icon":1}],"profile":{"websiteUrl":"http://www.springworkstx.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0.0051},{"period":"3month","weight":0.3648},{"period":"6month","weight":0.0928},{"period":"1year","weight":0.2269},{"period":"ytd","weight":0.3006}],"compareEarnings":[{"period":"1week","weight":0.0058},{"period":"1month","weight":0.0407},{"period":"3month","weight":0.1896},{"period":"6month","weight":0.0751},{"period":"1year","weight":0.1228},{"period":"ytd","weight":0.0648}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"SpringWorks Therapeutics, Inc.于2017年8月在特拉华州成立。该公司是一家临床阶段的生物制药公司，使用精密医学来为患有严重疾病和癌症的服务不足的患者人群获取，开发和商品化改变生命的药物。","yearOnYearQuotes":[{"month":1,"riseRate":0.666667,"avgChangeRate":0.053201},{"month":2,"riseRate":1,"avgChangeRate":0.12282},{"month":3,"riseRate":0,"avgChangeRate":-0.122128},{"month":4,"riseRate":0.333333,"avgChangeRate":-0.039357},{"month":5,"riseRate":0.666667,"avgChangeRate":-0.016314},{"month":6,"riseRate":0.666667,"avgChangeRate":0.047668},{"month":7,"riseRate":0.666667,"avgChangeRate":0.069774},{"month":8,"riseRate":0.4,"avgChangeRate":-0.018602},{"month":9,"riseRate":0.4,"avgChangeRate":-0.093177},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.012169},{"month":11,"riseRate":1,"avgChangeRate":0.184166},{"month":12,"riseRate":0.666667,"avgChangeRate":0.134333}],"exchange":"NASDAQ","name":"SpringWorks Therapeutics, Inc.","nameEN":"SpringWorks Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.34.3","shortVersion":"4.34.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"SpringWorks Therapeutics, Inc.(SWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供SpringWorks Therapeutics, Inc.(SWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"SpringWorks Therapeutics, Inc.,SWTX,SpringWorks Therapeutics, Inc.股票,SpringWorks Therapeutics, Inc.股票老虎,SpringWorks Therapeutics, Inc.股票老虎国际,SpringWorks Therapeutics, Inc.行情,SpringWorks Therapeutics, Inc.股票行情,SpringWorks Therapeutics, Inc.股价,SpringWorks Therapeutics, Inc.股市,SpringWorks Therapeutics, Inc.股票价格,SpringWorks Therapeutics, Inc.股票交易,SpringWorks Therapeutics, Inc.股票购买,SpringWorks Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"SpringWorks Therapeutics, Inc.(SWTX)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供SpringWorks Therapeutics, Inc.(SWTX)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}